Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Investment Income (2024)

Day One Biopharmaceuticals (DAWN) has disclosed Non Operating Investment Income for 1 consecutive years, with $108.0 million as the latest value for Q2 2024.

  • For Q2 2024, Non Operating Investment Income changed N/A year-over-year to $108.0 million; the TTM value through Jun 2025 reached $108.0 million, changed 0.0%, while the annual FY2024 figure was $108.0 million, N/A changed from the prior year.
  • Non Operating Investment Income was $108.0 million for Q2 2024 at Day One Biopharmaceuticals.
  • The five-year high for Non Operating Investment Income was $108.0 million in Q2 2024, with the low at $108.0 million in Q2 2024.